A potentially deadly disease known as “the white plague” has been rising in the U.S. since the pandemic, health officials have warned.

Tuberculosis (TB) gets its nickname from the pale appearance of those affected with the disease.

After a dip in 2020 with the onset of COVID – likely due to underdiagnosis and reduced screenings, according to health experts – cases of TB have increased every year since.

MENINGITIS CASES RISE IN MAJOR MIDWESTERN CITY, PROMPTING PUBLIC HEALTH ALERT

More than 10,600 cases were confirmed in 2024, which is around three people for every 100,000, per the latest available data from the Centers for Disease Control and Prevention.

This marks the third consecutive annual increase, and the total 2024 case count is the highest annual number since 2013.

Despite the recent increase, TB rates in the U.S. remain relatively low compared to many parts of the world, as the global average is about 131 cases per 100,000, per the World Health Organization. That’s approximately 40 times higher globally compared to the U.S.

TB is a curable bacterial infection that targets the lungs, but can also infect other organs, according to Johns Hopkins. It is spread through airborne particles released when an infected person coughs, speaks or sneezes.

URGENT WARNING ISSUED BY CDC AS CHIKUNGUNYA VIRUS OUTBREAK HITS VACATION DESTINATION

Renuga Vivekanandan, M.D., professor at Creighton University School of Medicine and VP and CMO of CHI Health Physician Enterprise Midwest, said the rise in tuberculosis cases in the U.S. is concerning, but noted that it was foreseeable.

“The COVID-19 pandemic effectively disrupted TB surveillance and treatment programs across the country,” the doctor, who is board-certified in internal medicine and infectious diseases, told Fox News Digital. 

“What we’re seeing now is largely a rebound effect – latent TB infections that went undetected or untreated during the pandemic are now activating.”

Another factor is a return to international travel and increased migration from countries where TB is more prevalent, according to Vivekanandan.

The uptick has also strained healthcare systems. “Local and state public health TB programs became understaffed during the pandemic, and that capacity hasn’t fully recovered,” the doctor said.

Symptoms of disease

While around 25% of people have likely been infected with the TB bacteria, about 5% to 10% will go on to develop active disease, according to health agencies.

MEASLES OUTBREAK POSES RISK OF ‘IRREVERSIBLE’ BRAIN DAMAGE, HEALTH OFFICIALS WARN

A person with a latent infection has been infected with the tuberculosis bacteria, but the bacteria are inactive in the body. While latent-stage TB is not contagious, it can develop into active disease in 5% to 10% of people. 

Only people with active TB disease in the lungs or throat can spread the infection.

Those who get sick with TB may experience mild symptoms, including coughing, chest pain, fatigue, weight loss, weakness, fever and night sweats, per the CDC. In some cases, however, the disease can also affect the kidneys, spine, skin and brain.

CLICK HERE FOR MORE HEALTH STORIES

“TB can affect any organ of the body, but it causes disease in the lung in over 80% of cases,” Masae Kawamura, M.D., a former TB control director in San Francisco and a tuberculosis clinician, previously told Fox News Digital. “This is dangerous because it causes cough, the mechanism of airborne spread.”

“TB can affect any organ of the body, but it causes disease in the lung in over 80% of cases.”

In more severe cases, patients may cough up blood, noted Kawamura, who serves on the board of directors of Vital Strategies, a global public health organization.

“Often, there are minimal symptoms for a long time, and people mistake their occasional cough with allergies, smoking or a cold they can’t shake off,” she added.

Risk factors, treatment and prevention

“The good news is that TB is both preventable and treatable,” Vivekanandan said.

“People who are at higher risk – including those born in or traveling frequently to high TB-burden countries, individuals living in crowded conditions, or those who are immunocompromised – should speak with their doctor about TB testing.”

Other high-risk groups include people who have diabetes, are malnourished, use tobacco and/or drink excess amounts of alcohol. Babies and children are also more vulnerable to the disease.

Doctors typically use a skin or blood test to detect TB infection, followed by imaging or sputum (mucus) testing to confirm active disease, per the CDC.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The disease is treated with antibiotics that are taken every day for four to six months, the CDC states. Some of the most common include isoniazid, rifampicin, pyrazinamide and ethambutol.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Failure to take the complete course of medications can cause the bacteria to become drug-resistant, which means it does not respond to standard antibiotics. Drug-resistant TB is more difficult and costly to treat and requires longer, more complex medication regimens, according to experts.

If TB goes untreated, it is fatal in about half of its victims.

“Latent TB, which causes no symptoms and is not contagious, can be treated and cured before it ever progresses to active TB, which is infectious,” Vivekanandan said.

“Identifying and treating latent infection is one of the most powerful tools we have for protecting both individual patients and the broader community.”

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ 

The U.S. Preventive Services Task Force recommends screening only for populations at increased risk rather than for the general population.

For women struggling with weight gain after menopause, a new study suggests that adding hormone therapy to a popular obesity drug may lead to greater weight loss.

Postmenopausal women lost about 35% more weight when using menopausal hormone therapy alongside tirzepatide — a GLP-1-based, Food and Drug Administration-approved drug for the overweight and obese — compared to those taking the drug alone, according to a Mayo Clinic study.

The findings, published in February in The Lancet Obstetrics, Gynaecology, & Women’s Health, highlight a possible new strategy for addressing weight gain after menopause, when hormonal shifts can increase the risk of obesity, cardiovascular disease and Type 2 diabetes.

STOPPING OZEMPIC? NEW STUDY REVEALS SURPRISING WEIGHT REGAIN RESULTS AFTER GLP-1S

“This study provides important insights for developing more effective and personalized strategies for managing cardiometabolic risk in postmenopausal women,” Dr. Regina Castaneda, the study’s first author, said in a statement. 

Researchers analyzed 120 postmenopausal women who were overweight or obese who took tirzepatide for at least 12 months, including 40 who also used hormone therapy and 80 who did not.

Hormone therapy is commonly used to treat menopause symptoms like hot flashes and night sweats, while tirzepatide helps regulate appetite and blood sugar.

WEIGHT LOSS MEDICATIONS COULD IMPACT SEXUAL HEALTH IN UNEXPECTED WAYS

Women in the hormone therapy group lost an average of 19.2% of their body weight, compared to 14.0% in the non-hormone group — about 35% greater relative weight loss — with more women reaching significant weight-loss thresholds, according to the study.

Despite the results, researchers emphasized that the study was observational and cannot prove cause and effect.

“Because this was not a randomized trial, we cannot say hormone therapy caused additional weight loss,” said Dr. Maria Daniela Hurtado Andrade, an endocrinologist at Mayo Clinic and senior author of the study.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Outside experts agree that the findings must be interpreted cautiously.

“As with all observational studies, we need to interpret this study with a grain of salt,” Dr. Gillian Goddard, a board-certified endocrinologist, told Fox News Digital. 

Goddard, who is also an adjunct assistant professor of medicine at the NYU Grossman School of Medicine, noted that the findings show a link but do not prove that hormone therapy, which usually includes estrogen, directly caused the additional weight loss.

CLICK HERE FOR MORE HEALTH STORIES

“There may be important differences between the two groups,” she added. “For one thing, the group taking estrogen may be healthier than the groups that didn’t take estrogen. … Healthier people are more likely to eat a healthy diet and exercise in addition to taking tirzepatide. That could lead to more weight loss.” 

Symptom relief from the therapy may have also improved sleep and well-being, making it easier for the group to maintain diet and exercise routines, Hurtado Andrade noted.

Researchers also pointed to a possible biological explanation. Preclinical data suggest estrogen may enhance the appetite-suppressing effects of GLP-1-based medications like tirzepatide, according to the study.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Goddard said that theory is plausible but unproven.

“The other possibility is that estrogen interacts with tirzepatide in some way that makes it more potent,” she said. “We will need randomized studies to get a better handle on that.”

As for safety, experts say using the two together appears safe for most women. However, hormone therapy is not recommended for all patients, especially those with a history of certain cancers, blood clots or other underlying health risks, according to the Mayo Clinic.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Researchers say future randomized trials will aim to confirm the findings and explore whether the combination also improves broader cardiometabolic health outcomes, according to the study.

“If confirmed, this work could speed the development and adoption of new, evidence-based strategies to reduce this risk for millions of postmenopausal women navigating this life stage,” Hurtado Andrade said.

Fox News Digital has reached out to the study authors for comment.

Use left and right arrow keys to navigate between menu items.

Use escape to exit the menu.